Regeneron Pharmaceuticals
Regeneron is seeking multiple 2027 Co-ops to join the Viral Production Core within Preclinical Manufacturing and Process Development. These full-time, onsite positions offer the opportunity to contribute to a science-driven organization developing life-changing medicines for serious diseases. Co-ops will work on processes used to produce and purify adeno-associated virus (AAV) for gene therapy programs.
Headquarters
Tarrytown, New York, United States
Company Size
10001+ employees
Founded
1988
Discover how Regeneron (NASDAQ: REGN) harmonizes biology and technology to create life-changing medicines. Join our team and explore clinical trials.
Quadrant Capital Group LLC Purchases 1,564 Shares of Regeneron Pharmaceuticals, Inc. $REGN
4 hours ago
In 2036, Investors Will Regret Not Loading Up on This Multibagger in the Making
6 hours ago
Will Positive Obesity Data and Dupixent Expansion Efforts Change Regeneron Pharmaceuticals' (REGN) Narrative?
1 day ago
Headquarters
San Francisco, CA
Company Size
201-500 employees
Founded
2018
Industry
Technology
Glassdoor Rating
4.2 / 5
Sarah Johnson
Chief Executive Officer
Michael Chen
Chief Technology Officer
Emily Williams
VP of Engineering
David Rodriguez
VP of Product
Jessica Thompson
Chief Financial Officer
Andrew Park
VP of Sales
View leadership team, funding history,
and employee contacts for Regeneron Pharmaceuticals.
Regeneron: Fairly Valued Now After A Stellar Upswing (NASDAQ:REGN)
1 day ago
Advisor, Downstream Process Development – Viral Vectors
Eli Lilly and Company
Master Thesis
Leica Biosystems
Postdoctoral Fellow in Pediatrics
PeopleAdmin
Post-Doc Research Associate
University of North Carolina at Chapel Hill
Scientist I/II, Viral Vector Process Development
Asimov
Post-Doc Research Associate
PeopleAdmin